scholarly journals Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells

2011 ◽  
Vol 39 (6) ◽  
pp. 653-665.e6 ◽  
Author(s):  
Gabriella Marfe ◽  
Carla Di Stefano ◽  
Alessandra Gambacurta ◽  
Tiziana Ottone ◽  
Valentina Martini ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Sphingosine Kinase ◽  
Leukemia Cells ◽  
Sphingosine Kinase 1 ◽  
Imatinib Resistant

scholarly journals Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells

Leukemia ◽  
2008 ◽  
Vol 22 (5) ◽  
pp. 971-979 ◽  
Author(s):  
E Bonhoure ◽  
A Lauret ◽  
D J Barnes ◽  
C Martin ◽  
B Malavaud ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Sphingosine Kinase ◽  
Leukemia Cells ◽  
Sphingosine Kinase 1 ◽  
Induced Apoptosis

Sphingosine Kinase 1 Is Involved in Proliferation and Survival of Chronic Myeloid Leukemia Cells.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4878-4878
Author(s):  
Clara Ricci ◽  
Francesco Onida ◽  
Davide Soligo ◽  
Giorgio Lambertenghi-Deliliers ◽  
Riccardo Ghidoni
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Cytotoxic Effect ◽  
Sphingosine Kinase ◽  
Leukemic Cells ◽  
Leukemia Cell Line ◽  
Leukemia Cells ◽  
Sphingosine Kinase 1 ◽  
Functional Link ◽  
Growth And Survival

Abstract Sphingosine Kinase 1 (SK1) is a key enzyme of the sphingolipid metabolism. By phosphorylating sphingosine (Sph), SK1 induces accumulation of sphingosine 1 phosphate (S1P). As a second messenger, S1P stimulates proliferation and survival and protects cells against ceramide-induced apoptosis. Although oncogenic activity of SK1 has been demonstrated in a variety of solid tumors, its role in leukemic cells growth remains unclear. Recently, SK1 overexpression has been reported to represent an oncogenic event during erythroleukemia progression (Lescolan E. et al, Blood 2005). We focused on Chronic Myeloid Leukemia (CML), a hematopoietic disorder characterized by the presence of the Philadelphia (Ph) chromosome that leads to the expression of the chimeric protein Bcr/Abl. Through its constitutive tyrosine kinase activity, Bcr/Abl is recognized as the pathogenetic event that causes CML and thus the basis for the development of specific inhibitors. Among these, Imatinib Mesylate (IM) represents the more successful drug for CML treatment. However, most patients who are treated in advanced stages of the disease relapse after an initial response to IM. Therefore, the existence of a functional link between Bcr/Abl and SK1 would provide new strategies to overcome acquired resistance to IM in CML. To test the hypothesis that SK1 contributes to the growth and survival of leukemic cells, we first verified that the kinase transcript is expressed in a panel of CML cell lines [AR230 (p230Bcr/Abl+), K562 and RWLeu4 (both p210Bcr/Abl+)], although at different levels. Then the effect of pharmacological inhibition of SK1 was assessed by using a competitive inhibitor (SKI, SK Inhibitor, Calbiochem) of the ATP-binding site of SK1. Cells were treated with increasing doses (1 to 50 μM) of SKI for up to 72 hrs and the WST-1 assay was performed. A dose- and time-dependent anti-proliferative and cytotoxic effect was observed (IC50: 7.02 μM for AR230, 7.06 μM for K562 and 35.8 μM for RWLeu4 cells). Surprisingly, up-regulation of SK1 transcript was detected. Finally, when the Eosinophilic Leukemia cell line Eol-1 (FIP1L1-PDGFRα+) was exposed to SKI under the same experimental conditions of CML cells, an even more potent anti-proliferative and cytotoxic effect was observed, indicating a higher sensitivity of these cells to SKI (IC50: 0.43 μM). Altogether our results suggest involvement of SK1 in the control of growth and survival of myeloid leukemia cells of different origin. To address the question whether a functional link between SK1 and Bcr/Abl occurs, we are now investigating if Bcr/Abl expression and phosphorylation status are modulated following treatment with SKI and conversely if SK1 expression and activity are affected by treatment with IM.

scholarly journals Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells

Oncogene ◽  
2007 ◽  
Vol 26 (57) ◽  
pp. 7904-7908 ◽  
Author(s):  
Q-F Li ◽  
W-R Huang ◽  
H-F Duan ◽  
H Wang ◽  
C-T Wu ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Sphingosine Kinase ◽  
Leukemia Cells ◽  
Sphingosine Kinase 1

scholarly journals Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells

Oncotarget ◽  
2011 ◽  
Vol 2 (11) ◽  
pp. 874-885 ◽  
Author(s):  
Maeva Dufies ◽  
Arnaud Jacquel ◽  
Nathalie Belhacene ◽  
Guillaume Robert ◽  
Thomas Cluzeau ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Leukemia Cells ◽  
Imatinib Resistant ◽  
And Function

5′-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells

2013 ◽  
Vol 37 (4) ◽  
pp. 427-433 ◽  
Author(s):  
Woo-Seok Kim ◽  
Min-Jung Lee ◽  
Do-Hyung Kim ◽  
Jung-Eun Lee ◽  
Jae-Il Kim ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Leukemia Cells ◽  
Imatinib Resistant
Sign in / Sign up

Export Citation Format

Share Document